Adverse events included, most commonly, grade 3 or 4 adverse events, specifically neutropenia and thrombocytopenia. Follicular lymphoma is a very diverse disease, and decisions to treat in the ...

Grade 2: 6 to 15 centroblasts/hpf (follicular mixed) Grade 3: with more than 15 centroblasts/hpf (follicular large cell) Grade 3: subdivided into grade 3a (centrocytes are present) and grade 3b ...

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory ...

What’s the next step for this patient with a 4-year history of low-grade follicular lymphoma and who now has worsening lymphadenopathy and needs a nap at the end of every work day? Share on ...

Most follicular lymphoma cases exhibit ... such as establishing the histologic grade and excluding a component of diffuse large B-cell lymphoma (DLBCL), she adds. PET-CT scans are helpful in ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

In total, 172 patients with follicular lymphoma were randomly assigned to one of two arms: six cycles of doxorubicin-based chemotherapy followed by maintenance therapy every other month for one ...

The most common grade 3 or 5 AEs with tafasitamab or placebo ... standard of care for patients with relapsed/refractory follicular lymphoma.” 1. Sehn LH, Luminari S, Scholz CW, et al.

The new use is the third for Kymriah (tisagenlecleucel) in the EU and offers patients with grade 1, 2 and 3A follicular lymphoma that has ... January @ 10 am ET - 3 pm GMT - 4 pm CET, in our ...

Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and ...